

RESEARCH

Open Access



# Construction of prediction models for novel subtypes in patients with arteriosclerosis obliterans undergoing endovascular therapy: an unsupervised machine learning study

Xiaocheng Li<sup>1</sup>, Lin Zhang<sup>1</sup>, Que Li<sup>1</sup>, Jiangfeng Zhang<sup>1</sup> and Xiao Qin<sup>1\*</sup>

## Abstract

**Background** Arteriosclerosis obliterans (ASO) is a chronic arterial disease that can lead to critical limb ischemia. Endovascular therapy is increasingly used for limb salvage in ASO patients, but the outcomes vary. The development of prediction models using unsupervised machine learning may lead to the identification of novel subtypes to guide patient prognosis and treatment.

**Methods** This retrospective study analyzed clinical data from 448 patients with ASOs who underwent endovascular therapy. Unsupervised machine learning algorithms were employed to identify subgroups. To validate the precision of the clustering outcomes, an analysis of the postoperative results of the clusters was conducted. A prediction model was constructed using binary logistic regression.

**Results** Two distinct subgroups were identified by unsupervised machine learning and characterized by differing patterns of clinical features. Patients in Cluster 2 had significantly worse conditions and prognoses than those in Cluster 1. For the novel ASO subtypes, a nomogram was developed using six predictive factors, namely, platelet count, ankle brachial index, Rutherford category, operation method, hypertension, and diabetes status. The nomogram achieved excellent discrimination for predicting membership in the two identified clusters, with an area under the curve of 0.96 and 0.95 in training cohort and internal test cohort.

**Conclusion** This study demonstrated that unsupervised machine learning can reveal novel phenotypic subgroups of patients with varying prognostic risk who underwent endovascular therapy. The prediction model developed could support clinical decision-making and risk counseling for this complex patient population. Further external validation is warranted to assess the generalizability of the findings.

**Keywords** Machine learning, Arteriosclerosis obliterans, Endovascular therapy, Cluster analysis, Prediction model

## Background

Peripheral Arterial Disease (PAD) is a prevalent circulatory condition marked by narrowed arteries, which impede blood flow to the limbs [1]. Arteriosclerosis Obliterans (ASO) constitutes a significant subset of PAD, representing the chronic advancement of arteriosclerotic disease. Patients with ASO typically present with symptoms ranging from intermittent claudication to more severe manifestations such as rest pain and tissue loss,

\*Correspondence:

Xiao Qin  
dr\_qinxiao@hotmail.com

<sup>1</sup> Department of Vascular Surgery Ward, The First Affiliated Hospital of Guangxi Medical University, No.6 of Shuangyong Road, Nanning, Guangxi 530021, P. R. China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

reflecting varying stages of disease severity [2]. Endovascular therapy has emerged as a promising approach for treating ASO patients, offering a less invasive alternative to traditional surgical procedures. However, significant variability exists in patient responses to this therapy, and accurately predicting outcomes remains challenging [3].

In recent years, advances in unsupervised machine learning (UMLA) techniques have opened new avenues for understanding the heterogeneity within ASO patients. These techniques facilitate the automatic clustering of patients into distinct subtypes based on diverse clinical and omics data [4]. This study aimed to evaluate the power of the UMLA to construct a prediction model that can identify novel subtypes within the ASO patient population undergoing endovascular therapy.

In this study, clinical data from ASO patients who underwent endovascular therapy were collected. Using UMLA, patient clustering into distinct groups based on their clinical characteristics was performed. Subsequently, a comparative analysis of surgical outcomes and postoperative complications between the identified patient groups was carried out to validate the accuracy of clustering. Finally, we examined the potential risk factors contributing to patient clustering with the aim of constructing a novel prediction model for ASO subtypes. This prediction model has the potential to guide clinicians in identifying patients at risk for poor outcomes, facilitating timely intervention and tailored therapeutic approaches.

## Methods

### Patients

This study is a single-center retrospective study. Clinical data were collected from patients diagnosed with ASO who underwent endovascular treatment for lower extremity conditions at Guangxi Medical University between January 2015 and January 2023. The inclusion criteria for patients were as follows: had (a) met the established diagnostic criteria for ASO in the lower limbs [5], (b) had undergone endovascular treatment for the lower extremities, (c) received ultrasound, computed tomography angiography (CTA), or digital subtraction angiography (DSA) to assess lower extremity artery occlusion, and (d) had complete clinical data available. The exclusion criteria included (a) loss to follow-up and (b) the presence of a malignant tumor. Based on the inclusion and exclusion criteria, a total of 448 eligible patients were included in the study.

We collected 18 preoperative variables and 10 postoperative variables. The 18 preoperative variables included sex, age, body mass index (BMI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), platelet count, ankle brachial index (ABI) [6],

Rutherford category [7], TransAtlantic Inter-Society Consensus (TASC) II classification [8], operative method, operation time and history of smoking, hypertension, diabetes, cardiovascular heart disease (CAD), cerebrovascular disease (CVD) and chronic kidney disease (CKD). The 10 postoperative variables were the degree of claudication and tissue loss, ischemic rest pain, multiple organ dysfunction syndrome (MODS), renal failure, wound infection, wound ulceration, amputation, death in hospital, and septicemia. All the postoperative outcomes were assessed during the 30-day follow-up.


This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of The First Affiliated Hospital of Guangxi Medical University.

### Clustering clinical data using UMLA

K-means clustering algorithm was used to cluster the ASO patients. K-means clustering is a widely used unsupervised learning method for discovering distinct groupings in data by minimizing within-cluster variation. The algorithm steps are as follows: (a) randomly initialize  $k$  cluster centroids; (b) assign each data point to the nearest cluster; (c) recompute cluster centroids based on assigned points; and (d) repeat steps 2–3 until the centroids no longer change or the maximum number of iterations is reached [9]. Figure 1A shows the K-means algorithm flow. R software version 4.2.1 employed the scale function from the ‘factoextra’ package to standardize the preoperative variables of ASO patients [10]. The optimal number of clusters (K-value) was determined using the ‘fpc’ package, which calculated the silhouette coefficient (SC). The silhouette coefficient is a metric utilized to assess the clustering performance of an unsupervised learning model, measuring the degree to which each data point fits into its assigned cluster [11].

$$SC(i) = \frac{b(i) - a(i)}{\max\{a(i), b(i)\}}$$

Where  $SC(i)$  denotes a calculated score that evaluates the quality of the cluster. For each data point  $i$ ,  $a(i)$  constitutes the average distance from  $i$  to all other points within its cluster, while  $b(i)$  represents the minimum average distance  $i$  of to points in any different cluster. The overall SC of the model is determined by averaging the silhouette scores of all data points. Scores approaching +1 suggest dense, well-separated clusters; scores around 0 imply overlapping clusters; and negative scores may signify incorrect assignment of points to clusters. In essence, SC serves as a quantitative measure for assessing the suitability of data clustering by a specific model and is instrumental in evaluating



**Fig. 1** Result of unsupervised machine learning. **A** Optimal clustering number of the K-means clustering algorithm was determined by Silhouette coefficient (SC). The peak of the curve is the best value for the Silhouette coefficient (Y-axis); the best number of clusters was equal to 2 (X-axis). **B** Scatter plots of patients’ clinical data. Scatter points on the graph represent each patient. The K-means algorithm divides patients into two clusters. The red scatter represents cluster 1 and the blue scatter represents cluster 2

and refining the configuration of unsupervised learning clustering algorithms [12].

Based on the preoperative data, patients were divided into two clusters according to the UMLA, after which the differences in the postoperative data between the two clusters were analyzed to verify the accuracy of the UMLA clustering.

**Construction of the prediction model**

The dataset was randomly divided into training and validation cohorts at a ratio of 7:3, and the variables were compared. In the training cohort, the least absolute shrinkage and selection operator (LASSO) logistic regression analysis was used for multivariate analysis to screen the independent risk factors. The training dataset was then utilized to develop a multivariate logistic regression model. The coefficients from this model were employed to construct the nomogram. The nomogram mapped the logistic regression coefficients to a 0–100 scale to provide a visual representation of the predicted probabilities [13]. The performance of the nomogram was assessed using the receiver operating characteristic (ROC) curve and calibration curve, with the area under the ROC curve (AUC) ranging from 0.5 (no discriminant) to 1 (complete discriminant). Additionally, a decision curve analysis (DCA) was conducted to establish the net benefit threshold for prediction.

**Statistical analysis**

IBM SPSS 26.0 and R 4.2.1 software were used for statistical analysis. Clinical data are presented as the mean (SD) and median (P25, P75). Depending on the data type, Student’s t-test, the Mann–Whitney U test, or the chi-square test was performed. A *p*-value < 0.05 was considered to indicate statistical significance.

**Results**

**Results of UMLA**

Figure 1B displays the optimal clustering number determined by the K-means algorithm, with the peak of the curve indicating the best value for the SC (Y-axis) [14]. This suggests that two is the optimal number of clusters. Consequently, the algorithm effectively clustered the current clinical data into two clusters (Fig. 1C). Table 1 presents the K-means clustering results for the clinical data. The sex distribution was significantly different between the two clusters (*p* = 0.002), with cluster 2 having a greater proportion of males (71%) than cluster 1 (56%). Age, body mass index (BMI), total cholesterol (TC), platelet count, low-density lipoprotein cholesterol (LDL-C), Rutherford category, smoking status, hypertension, and diabetes incidence were significantly greater in cluster 2 than in cluster 1 (*p* < 0.05). The ankle brachial index (ABI) in cluster 2 was significantly lower than that in cluster 1 (*p* < 0.001). According to the TransAtlantic Inter-Society Consensus (TASC) II classification, a

**Table 1** Preoperative conditions of the study patients by clusters

| Characteristic             | cluster           |                   | p-value |
|----------------------------|-------------------|-------------------|---------|
|                            | 1, N=243          | 2, N=205          |         |
| <b>Age</b>                 |                   |                   | 0.001   |
| Mean ± SD                  | 58 ± 12           | 61 ± 12           |         |
| Median (IQR)               | 56 (49, 68)       | 62 (52, 70)       |         |
| <b>BMI</b>                 |                   |                   | 0.007   |
| Mean ± SD                  | 22.5 ± 3.8        | 23.1 ± 3.3        |         |
| Median (IQR)               | 22.0 (20.0, 24.6) | 23.1 (20.5, 25.5) |         |
| <b>TC</b>                  |                   |                   | 0.002   |
| Mean ± SD                  | 7.5 ± 3.6         | 8.7 ± 4.3         |         |
| Median (IQR)               | 6.7 (5.1, 9.1)    | 7.5 (5.9, 10.3)   |         |
| <b>Platelet</b>            |                   |                   | 0.009   |
| Mean ± SD                  | 210 ± 79          | 247 ± 123         |         |
| Median (IQR)               | 209 (154, 257)    | 227 (165, 285)    |         |
| <b>LDL-C</b>               |                   |                   | 0.009   |
| Mean ± SD                  | 5.40 ± 2.67       | 6.48 ± 3.77       |         |
| Median (IQR)               | 4.74 (3.60, 7.17) | 5.79 (3.62, 8.48) |         |
| <b>TG</b>                  |                   |                   | 0.618   |
| Mean ± SD                  | 1.55 ± 0.66       | 1.50 ± 0.62       |         |
| Median (IQR)               | 1.56 (1.06, 1.89) | 1.51 (1.06, 1.89) |         |
| <b>ABI</b>                 |                   |                   | <0.001  |
| Mean ± SD                  | 0.64 ± 0.13       | 0.39 ± 0.15       |         |
| Median (IQR)               | 0.67 (0.55, 0.74) | 0.38 (0.29, 0.46) |         |
| <b>Rutherford category</b> |                   |                   | <0.001  |
| Mean ± SD                  | 2.35 ± 0.76       | 4.58 ± 1.29       |         |
| Median (IQR)               | 2.00 (2.00, 2.00) | 5.00 (4.00, 6.00) |         |
| <b>Gender</b>              |                   |                   | 0.002   |
| Female                     | 106 (44%)         | 60 (29%)          |         |
| Male                       | 137 (56%)         | 145 (71%)         |         |
| <b>Smoking</b>             |                   |                   | <0.001  |
| No                         | 102 (42%)         | 55 (27%)          |         |
| Yes                        | 141 (58%)         | 150 (73%)         |         |
| <b>Hypertension</b>        |                   |                   | <0.001  |
| No                         | 178 (73%)         | 106 (52%)         |         |
| Yes                        | 65 (27%)          | 99 (48%)          |         |
| <b>Diabetes</b>            |                   |                   | 0.007   |
| No                         | 196 (81%)         | 143 (70%)         |         |
| Yes                        | 47 (19%)          | 62 (30%)          |         |
| <b>CAD</b>                 |                   |                   | 0.478   |
| No                         | 226 (93%)         | 194 (95%)         |         |
| Yes                        | 17 (7%)           | 11 (5%)           |         |
| <b>CVD</b>                 |                   |                   | 0.348   |
| No                         | 226 (93%)         | 195 (95%)         |         |
| Yes                        | 17 (7%)           | 10 (5%)           |         |
| <b>CKD</b>                 |                   |                   | 0.802   |
| No                         | 220 (91%)         | 187 (91%)         |         |
| Yes                        | 23 (9%)           | 18 (9%)           |         |
| <b>TASC II</b>             |                   |                   | <0.001  |
| A                          | 121 (50%)         | 4 (2%)            |         |
| B                          | 107 (44%)         | 14 (7%)           |         |

**Table 1** (continued)

| Characteristic            | cluster   |           | p-value |
|---------------------------|-----------|-----------|---------|
|                           | 1, N=243  | 2, N=205  |         |
| C                         | 15 (6%)   | 117 (57%) |         |
| D                         | 0 (0%)    | 70 (34%)  |         |
| <b>Operative method</b>   |           |           | <0.001  |
| PTA                       | 38 (16%)  | 109 (53%) |         |
| Atherectomy + PTA         | 124 (51%) | 41 (20%)  |         |
| Atherectomy + PTA + Stent | 81 (33%)  | 55 (27%)  |         |
| <b>Operation time</b>     |           |           | <0.001  |
| < 2h                      | 76 (31%)  | 52 (25%)  |         |
| 2~4h                      | 124 (51%) | 78 (38%)  |         |
| >4h                       | 43 (18%)  | 75 (37%)  |         |

ABI Ankle brachial index, BMI Body mass index, CAD Coronary artery disease, CVD Cerebrovascular disease, CKD Chronic kidney disease, LDL-C Low-density lipoprotein cholesterol, PTA Percutaneous transluminal angioplasty, TASC II TransAtlantic Inter-Society Consensus II, TC Total cholesterol, TG triglyceride


greater proportion of patients with type C and D lesions was observed in cluster 2, while type A and B lesions were more prevalent in cluster 1 ( $p < 0.001$ ). Furthermore, significant differences existed between the two clusters in terms of the operation method and duration. No significant differences were noted in the other preoperative variables. Figure 2A displays the radargram of the preoperative variables.

**Comparison of postoperative variables between the two clusters**

Table 2 illustrates the differences in postoperative variables between the two clusters. Cluster 2 exhibited a greater incidence of renal failure than did cluster 1 ( $p = 0.036$ ). Furthermore, the incidence of wound infection, ulceration, and amputation in cluster 2 was significantly greater than that in cluster 1 ( $p < 0.001$ ). Additionally, claudication, ischemic rest pain, and tissue loss were more severe in cluster 2 than in cluster 1 ( $p < 0.001$ ). These results indicated worse prognoses and outcomes for patients in cluster 2 than for those in cluster 1 (Fig. 2B). The differences in postoperative variables between the two clusters confirmed the accuracy of UMLA clustering in this study. Hence, UMLA successfully stratified ASO patients into severe and mild cohorts based on the acquired clinical data.

**Construction of a prediction model for the novel ASO subtype**

This study examined the clinical data of 448 ASOs, divided into a Training Cohort comprising 314 individuals and an Internal Test Cohort with 134 participants. Supplementary Table 1 displays the baseline



**Fig. 2** Radargram of LE-PAD patients’ preoperative and postoperative variables in two clusters. **A** Radargram of LE-PAD patients’ preoperative variables in two clusters. **B** Radargram of LE-PAD patients’ postoperative variables in two clusters. ABI: Ankle brachial index; BMI: Body mass index; CAD: Coronary artery disease; CVD: Cerebrovascular disease; CKD: Chronic kidney disease; LDL-C: Low-density lipoprotein cholesterol; MODS: multiple organ dysfunction syndrome; PTA: Percutaneous transluminal angioplasty; TASC II: Inter-society consensus for the management of peripheral arterial disease; TC: Total cholesterol; TG: triglyceride

**Table 2** Postoperative conditions of patients in two clusters

| Characteristic            | cluster   |           | p-value |
|---------------------------|-----------|-----------|---------|
|                           | 1, N=243  | 2, N=205  |         |
| <b>Claudication</b>       |           |           | <0.001  |
| Asymptomatic              | 222 (91%) | 114 (56%) |         |
| Mild                      | 12 (5%)   | 55 (27%)  |         |
| Moderate                  | 6 (2%)    | 26 (13%)  |         |
| Severe                    | 3 (1%)    | 10 (5%)   |         |
| <b>Ischemic rest pain</b> |           |           | <0.001  |
| No                        | 234 (96%) | 158 (77%) |         |
| Yes                       | 9 (4%)    | 47 (23%)  |         |
| <b>Tissue loss</b>        |           |           | <0.001  |
| No                        | 231 (95%) | 152 (74%) |         |
| Minor                     | 7 (3%)    | 43 (21%)  |         |
| Major                     | 5 (2%)    | 10 (5%)   |         |
| <b>MODS</b>               |           |           | 0.825   |
| No                        | 235 (97%) | 199 (97%) |         |
| Yes                       | 8 (3%)    | 6 (3%)    |         |
| <b>Renal failure</b>      |           |           | 0.036   |
| No                        | 238 (98%) | 193 (94%) |         |
| Yes                       | 5 (2%)    | 12 (6%)   |         |
| <b>Infection</b>          |           |           | <0.001  |
| No                        | 237 (98%) | 166 (81%) |         |
| Yes                       | 6 (2%)    | 39 (19%)  |         |
| <b>Ulceration</b>         |           |           | <0.001  |
| No                        | 241 (99%) | 171 (83%) |         |
| Yes                       | 2 (1%)    | 34 (17%)  |         |
| <b>Amputation</b>         |           |           | <0.001  |
| No                        | 226 (93%) | 157 (77%) |         |
| Yes                       | 17 (7%)   | 48 (23%)  |         |
| <b>Death</b>              |           |           | 0.077   |
| No                        | 236 (97%) | 192 (94%) |         |
| Yes                       | 7 (3%)    | 13 (6%)   |         |
| <b>Septicopyemia</b>      |           |           | 0.592   |
| No                        | 235 (97%) | 200 (98%) |         |
| Yes                       | 8 (3%)    | 5 (2%)    |         |

MODS multiple organ dysfunction syndrome

demographic and clinical features of the respective cohorts. Next, the candidate predictors were included in the original model, which were then reduced to 6 potential predictors using LASSO regression analysis performed in the training cohort. The cross-validation plot of the LASSO regression model is plotted in the Fig. 3A. A coefficient path plot is also shown in the Fig. 3B. The most regularized and parsimonious model, with a cross-validated error within one standard error of the minimum, included six variables. As shown in Fig. 3C, the ROC analysis of the abovementioned variables yielded AUC values greater than 0.5. Further multivariate logistic

analyses were carried out in different clusters. Results are shown in the Table 3. The final logistic model included 6 independent predictors (hypertension, diabetes, platelet, ABI, rutherford classification, and operation method) and was developed as a simple-to-use nomogram, which is illustrated in the Fig. 3D. The AUCs of the model in the different cohorts were 0.96 and 0.95 (Fig. 4A). The calibration plots of the nomogram in the different cohorts are plotted in the Fig. 4 B-C, which demonstrate a good correlation between the observed and predicted cluster. The results showed that the original nomogram was still valid for use in the validation sets, and the calibration curve of this model was relatively close to the ideal curve, which indicates that the predicted results were consistent with the actual findings. Figure 4D-E display the DCA curves related to the nomogram. A high-risk threshold probability indicates the chance of significant discrepancies in the model's prediction when clinicians encounter major flaws while utilizing the nomogram for diagnostic and decision-making purposes. This research shows that the nomogram offers substantial net benefits for clinical application through its DCA curve.


## Discussion

### Clinical significance of UMLA modeling of the novel ASO subtype

With the advancement of artificial intelligence (AI), UMLA has found extensive application in clinical research. For instance, Eshaghi et al. employed UMLA to categorize multiple sclerosis patients into pathology-based subtypes utilizing magnetic resonance imaging [15]. Kung et al. identified depression subtypes using UMLA on symptom data from more than 18,000 patients [16]. These studies demonstrated the potential of using UMLA to discover novel subtypes and construct prediction models. Establishing accurate subtyping and risk prediction enables precision medicine approaches for these complex, heterogeneous diseases.

Compared to supervised machine learning and traditional predictive modeling approaches, UMLA excels in uncovering hidden patterns and structures within the data without prior labeling [17]. This is particularly advantageous in medical research where the complexity and variability of clinical data often mask underlying patterns that could be crucial for patient stratification and outcome prediction. By leveraging UMLA, we identified distinct subtypes of ASO patients that might not have been evident through traditional methods.

Additionally, unlike supervised machine learning, UMLA groups patients based on inherent similarities in their clinical features. This data-driven approach enables the identification of patient subgroups that share common characteristics and potentially similar prognostic



**Fig. 3** Construction of the predictive model. **A** Cross-validation plot of the LASSO regression model. **B** Coefficient path plot of the LASSO regression model. **C** ROC curve analysis of the six candidate diagnostic indicators. **D** Nomogram for prediction model. ABI: Ankle brachial index; AUC: Area under the curve; PTA: Percutaneous transluminal angioplasty

**Table 3** Results of Multivariate Logistic regression for Training Cohort

| Characteristic                   | N   | Event N | OR <sup>1</sup> | 95% CI <sup>1</sup> | p-value |
|----------------------------------|-----|---------|-----------------|---------------------|---------|
| <b>Hypertension</b>              |     |         |                 |                     |         |
| No                               | 208 | 72      | —               | —                   |         |
| Yes                              | 106 | 68      | 4.02            | 1.68, 9.61          | 0.002   |
| <b>Diabetes</b>                  |     |         |                 |                     |         |
| No                               | 239 | 92      | —               | —                   |         |
| Yes                              | 75  | 48      | 4.42            | 1.56, 12.50         | 0.005   |
| <b>Platelet</b>                  |     |         |                 |                     |         |
|                                  | 314 | 140     | 1.01            | 1.00, 1.01          | 0.010   |
| <b>ABI</b>                       |     |         |                 |                     |         |
|                                  | 314 | 140     | 0.01            | 0.00, 0.15          | 0.002   |
| <b>Rutherford classification</b> |     |         |                 |                     |         |
|                                  | 314 | 140     | 3.80            | 2.43, 5.94          | <0.001  |
| <b>Operative method</b>          |     |         |                 |                     |         |
| PTA                              | 100 | 73      | —               | —                   |         |
| Atherectomy + PTA                | 121 | 33      | 0.19            | 0.07, 0.52          | 0.001   |
| Atherectomy + PTA + Stent        | 93  | 34      | 0.39            | 0.12, 1.24          | 0.109   |


ABI Ankle brachial index, PTA Percutaneous transluminal angioplasty

trajectories [18]. Such stratification is essential for personalized medicine, allowing for tailored treatment strategies that could improve patient outcomes.

Furthermore, UMLA models are highly adaptable and can be applied to various types of data, including continuous, categorical, and binary variables [19]. This flexibility is beneficial in the medical field where patient data is often heterogeneous. UMLA can be continuously refined and updated as new data becomes available, ensuring that the predictive models remain relevant and accurate over time.

In the current study, UMLA categorized 18 predictor variables derived from the information of ASO patients into two distinct clusters: cluster 1 and cluster 2. Further analysis of postoperative variables in these two clusters revealed significantly worse conditions and prognoses for patients in the cluster 2 cohort. This subtyping system provides preliminary evidence that ASOs may represent multiple biological entities with varying prognostic risks.

The nomogram created in this study may have clinical utility for individual risk stratification. By incorporating



**Fig. 4** Validation of the predictive model of the predictive model. **A** ROC curves of the nomogram predictive model. **B** Calibration curve of the nomogram predictive mode for the training cohort. **C** Calibration curve of the nomogram prediction mode for the internal test cohort. **D** Decision curve analysis of the nomogram of the training cohort. **E** Decision curve analysis of the nomogram of the internal test cohort. AUC: Area under the curve



a set of clinical variables, the nomogram demonstrated outstanding discrimination in predicting membership in the two identified clusters, achieving an AUCs of 0.96 and 0.95 in training cohort and internal test cohort. If validated, this model could be utilized to customize treatment strategies based on the anticipated disease trajectory. Patients at high risk might benefit from more intensive follow-up and monitoring, whereas low-risk patients could potentially avoid unnecessary interventions.

Several limitations should be noted. However, our model requires external validation in diverse patient cohorts before clinical implementation. Additionally, The k-means clustering results reveal a relatively low silhouette coefficient, albeit still within an acceptable range. This finding suggests that the severity of ASO among patients likely exists along a spectrum rather than discrete clusters. Future studies could benefit from incorporating additional variables, including genetic, biomarker, and imaging data, to enhance clustering performance [20]. Nonetheless, this study offers a proof-of-concept for an AI-driven approach to unraveling heterogeneity and facilitating personalized medicine in ASO patients. With additional validation and fine-tuning, machine learning models could be integrated into clinical decision support systems to assist in tailoring individualized treatments. In summary, advanced analytics hold significant potential for discovering new insights into the disease and enhancing outcomes for this intricate vascular disorder.

#### **Analysis of risk factors for poor prognosis after endovascular therapy in patients with ASO**

In this study, hypertension, diabetes status, high platelet count, low ABI and advanced Rutherford category were identified as independent risk factors for poor prognosis after endovascular therapy in patients who underwent ASO. On the contrary, the combination of atherectomy and percutaneous transluminal angioplasty was observed to have a protective effect against adverse outcomes.

Abnormal glucose metabolism has been recognized as a substantial risk factor for the progression of atherosclerosis [21]. Dysregulated blood glucose can disrupt autonomic function, elevate oxidative stress, inflict damage on the vascular endothelium, and foster the formation of atherosclerotic plaques. Among individuals with diabetes and concurrent ASO, there is a tendency for the involvement of the femoral profunda and infrapatellar arteries in both lower extremities. These affected vessels tend to be small in caliber with extensive branching, predisposing diabetic ASO patients to high rates of restenosis and reocclusion after surgical revascularization [22].

Platelets, which are anuclear cells involved in inflammation, play a significant role in the development and

complications of atherosclerosis. Upon activation, these cells release a variety of chemokines, promoting localized inflammation at vascular injury sites. This process results in pathogenic intimal thickening and contributes to vascular obstruction [23]. Additionally, endovascular procedures may trigger thrombus formation. Platelets perceive artificial grafts as foreign entities and undergo activation upon contact with the graft surface. This activation can lead to early postoperative vascular obstruction, particularly when grafts are placed distally to the popliteal artery. Consequently, long-term antiplatelet therapy is often advised for patients receiving artificial vascular grafts [24].

Our study suggests that atherectomy+PTA is a protective factor for poor prognosis in ASO patients undergoing endovascular therapy. Atherectomy entails the physical removal of atherosclerotic plaque from the arterial lumen, thereby reducing the overall plaque burden. This debulking process promotes the creation of a larger and more uniform lumen, facilitating improved blood flow and lowering the risk of restenosis [25]. Furthermore, atherectomy eliminates calcified and fibrotic plaques, enhancing the compliance of the treated vessel segment. Consequently, this improves the efficacy of subsequent PTA by enabling better balloon expansion and more effective dilatation of the vessel. Additionally, the combined use of atherectomy and PTA may induce a more favorable healing response by generating a smoother luminal surface, potentially reducing the likelihood of neointimal hyperplasia, a common cause of restenosis following angioplasty [26].

Regarding the necessity for stent placement, it is crucial to recognize that this decision often reflects the severity and complexity of peripheral vascular disease. Patients requiring stents typically present with advanced disease characterized by extensive and complex lesions prone to elastic recoil or dissection following angioplasty [27]. This necessity underscores a challenging clinical scenario, inherently associated with a higher risk of adverse outcomes.

However, it is crucial to emphasize that the choice of surgical method for ASO patients should always be tailored to the specific conditions of the patient's arteries. The decision-making process must consider various factors, including the extent and location of the arterial lesions, the overall health of the patient, and any comorbid conditions that may influence the outcome of the procedure [28]. Despite these considerations, the results of our study are promising. They indicate that atherectomy+PTA can be highly effective in managing ASO. Future research should focus on further refining patient selection criteria and exploring the long-term

benefits of this combined therapeutic approach to maximize patient outcomes.

In conclusion, a majority of patients with ASOs possess multiple risk factors, the cumulative effects of which can accelerate atherosclerotic processes. Our study demonstrated the potential of using the UMLA to identify novel subtypes and construct prediction models in ASO patients receiving endovascular therapy. The current prediction model has the potential to stratify ASO risk, facilitating personalized care through medications, lifestyle adjustments, vigilant monitoring, and timely interventions. Nonetheless, additional validation and enhancement of the model are necessary before its clinical implementation. In summary, the combination of machine learning with precision medicine represents a promising approach to enhance outcomes in patients undergoing endovascular therapy for ASO.

## Conclusions

This study demonstrated that unsupervised machine learning can uncover novel phenotypic subgroups of ASO patients who are receiving endovascular therapy and who are at varying prognostic risk. The prediction model developed could support clinical decision-making and risk counseling for this complex patient population. Further external validation is warranted to assess the generalizability of the findings.

## Abbreviations

|         |  |
|---------|--|
| ABI     | Ankle-brachial index                     |
| AUC     | Area under the curve                     |
| ASO     | Arteriosclerosis obliterans              |
| BMI     | Body mass index                          |
| CAD     | Coronary artery disease                  |
| CVD     | Cerebrovascular disease                  |
| CKD     | Chronic kidney disease                   |
| CI      | Confidence interval                      |
| LDL-C   | Low-density lipoprotein cholesterol      |
| MODS    | Multiple organ dysfunction syndrome      |
| PTA     | Percutaneous transluminal angioplasty    |
| ROC     | Receiver operating characteristic        |
| SC      | Silhouette coefficient                   |
| TASC II | TransAtlantic Inter-Society Consensus II |
| TC      | Total cholesterol                        |
| TG      | Triglyceride                             |
| UMLAs   | Unsupervised machine learning algorithms |

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13019-024-02913-6>.

Supplementary Material 1.

## Acknowledgements

The authors are very grateful to Prof. Xiao Qin (Vascular Surgery Ward, The First Affiliated Hospital of Guangxi Medical University) for support in all stages of this study.

## Authors' contributions

XL contributed to the conception and design of the study, interpretation of the data, writing the manuscript, and critical revision of the article. LZ contributed to the study development, data acquisition and analysis, drafting the manuscript, and critical revision of the article. QL and JZ contributed to manuscript editions and critical revision of the article. XQ contributed to the conception of the study and critical revision of the article. All authors read and approved the final version of the manuscript.

## Funding

This work was supported by the National Natural Science Foundation of China [grant numbers: 81960091].

## Availability of data and materials

No datasets were generated or analysed during the current study.

## Declarations

### Ethics approval and consent to participate

All the procedures in this study were approved by the Ethics Committee of The First Affiliated Hospital of Guangxi Medical University (approval number: 2023-E558-01). This study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki. The requirement for informed consent from the study subjects was waived by the Ethics Committee of The First Affiliated Hospital of Guangxi Medical University due to the retrospective study design.

### Consent for publication

Not applicable.

### Competing interests

The authors declare no competing interests.

Received: 9 January 2024 Accepted: 15 June 2024

Published online: 25 June 2024

## References

- Lian W, Nie H, Yuan Y, Wang K, Chen W, Ding L. Clinical Significance of Endothelin-1 And C Reaction Protein in Restenosis After the Intervention of Lower Extremity Arteriosclerosis Obliterans. *Journal of investigative surgery : the official journal of the Academy of Surgical Research*. 2021;34(7):765–70.
- Takahara M. Diabetes Mellitus and Lower Extremity Peripheral Artery Disease. *JMA journal*. 2021;4(3):225–31.
- Zheng YH, Song XT. Progress and prospect of the treatment of lower extremity arteriosclerosis obliterans. *Zhonghua wai ke za zhi [Chinese journal of surgery]*. 2021;59(12):961–4.
- Eckhardt CM, Madjarova SJ, Williams RJ, Ollivier M, Karlsson J, Pareek A, et al. Unsupervised machine learning methods and emerging applications in healthcare. *Knee Surg Sports Traumatol Arthrosc*. 2023;31(2):376–81.
- Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. *J Vasc Surg*. 2015;61(3 Suppl):2S–41S.
- Hawkins KE, Valentine RJ, Duke JM, Wang Q, Reed AB. Ankle-brachial index use in peripheral vascular interventions for claudication. *J Vasc Surg*. 2022;76(1):196–201.
- Rieß HC, Debus ES, Schwaneberg T, Hischke S, Maier J, Bublitz M, et al. Indicators of outcome quality in peripheral arterial disease revascularisations - a Delphi expert consensus. *Vasa*. 2018;47(6):491–7.
- Biagioni RB, Brandão GD, Biagioni LC, Nasser F, Burihan MC, Ingrand JC. Endovascular treatment of TransAtlantic Inter-Society Consensus II D femoropopliteal lesions in patients with critical limb ischemia. *J Vasc Surg*. 2019;69(5):1510–8.

9. Chantraine F, Schreiber C, Pereira JAC, Kaps J, Dierick F. Classification of stiff-knee gait kinematic severity after stroke using retrospective k-means clustering algorithm. *J Clin Med*. 2022;11(21):6270.
10. Garcia-Rudolph A, Garcia-Molina A, Opiiso E, Tormos MJ. Personalized Web-Based Cognitive Rehabilitation Treatments for Patients with Traumatic Brain Injury: Cluster Analysis. *JMIR Med Inform*. 2020;8(10):e16077.
11. Mationg MLS, Williams GM, Tallo VL, Olveda RM, Aung E, Alday P, et al. Determining the Impact of a School-Based Health Education Package for Prevention of Intestinal Worm Infections in the Philippines: Protocol for a Cluster Randomized Intervention Trial. *JMIR Res Protoc*. 2020;9(6):e18419.
12. Lovmar L, Ahlford A, Jonsson M, Syvänen AC. Silhouette scores for assessment of SNP genotype clusters. *BMC Genomics*. 2005;6:35.
13. Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, et al. Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer. *J Clin Oncol*. 2016;34(18):2157–64.
14. Kim H, Kim YH, Kim SJ, Choi MT. Pathological gait clustering in post-stroke patients using motion capture data. *Gait Posture*. 2022;94:210–6.
15. Eshaghi A, Young AL, Wijeratne PA, Prados F, Arnold DL, Narayanan S, et al. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. *Nat Commun*. 2021;12(1):2078.
16. Kung B, Chiang M, Perera G, Pritchard M, Stewart R. Unsupervised Machine Learning to Identify Depressive Subtypes. *Healthc Inform Res*. 2022;28(3):256–66.
17. Su QH, Chiang KN. Predicting Wafer-Level Package Reliability Life Using Mixed Supervised and Unsupervised Machine Learning Algorithms. *Materials (Basel, Switzerland)*. 2022;15(11):3897.
18. Marriott H, Kabiljo R, Hunt GP, Khleifat AA, Jones A, Troakes C, et al. Unsupervised machine learning identifies distinct ALS molecular subtypes in post-mortem motor cortex and blood expression data. *Acta Neuropathol Commun*. 2023;11(1):208.
19. Bhattacharyya T, Nayak S, Goswami S, Gadiyaram V, Mathew OK, Sowdhamini R. PASS2.7: a database containing structure-based sequence alignments and associated features of protein domain superfamilies from SCOPe. *Database*. 2022;2022:baac025.
20. Haug CJ, Drazen JM. Artificial Intelligence and Machine Learning in Clinical Medicine, 2023. *N Engl J Med*. 2023;388(13):1201–8.
21. Tang YD, Wang W, Yang M, Zhang K, Chen J, Qiao S, et al. Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial. *Circulation*. 2018;137(21):2231–45.
22. Lee MS, Rha SW, Han SK, Choi BG, Choi SY, Ali J, et al. Comparison of diabetic and non-diabetic patients undergoing endovascular revascularization for peripheral arterial disease. *J Invasive Cardiol*. 2015;27(3):167–71.
23. Bakogiannis C, Sachse M, Stamatelopoulos K, Stellos K. Platelet-derived chemokines in inflammation and atherosclerosis. *Cytokine*. 2019;122:154157.
24. Habib A, Finn AV. Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. *Pharmacol Res*. 2015;93:22–7.
25. Zhu Z, Chen L, Yu W, Gao C, He B. Numerical Analysis of Stress Force on Vessel Walls in Atherosclerotic Plaque Removal through Coronary Rotational Atherectomy. *Micromachines*. 2023;14(12):2148.
26. Sanon O, Carnevale M, Indes J, Gao Q, Lipsitz E, Koleilat I. Incidence of procedure-related complications in patients treated with atherectomy in the femoropopliteal and tibial vessels in the vascular quality initiative. *J Endovasc Ther: an official journal of the International Society of Endovascular Specialists*. 2023;30(5):693–702.
27. Tepe G, Brodmann M, Micari A, Scheinert D, Choi D, Menk J, et al. 5-Year Outcomes of Drug-Coated Balloons for Peripheral Artery In-Stent Restenosis, Long Lesions, and CTOs. *JACC Cardiovasc Interv*. 2023;16(9):1065–78.
28. Barbarawi M, Qazi AH, Lee J, Barbarawi O, Al-Abdoun A, Mhanna M, et al. Meta-analysis comparing drug-coated balloons and percutaneous transluminal angioplasty for infrapopliteal artery disease. *Am J Cardiol*. 2022;183:115–21.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.